MI Visit the ASPET Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Molecular Interventions 5:358-367, (2005)
© American Society for Pharmacology and Experimental Therapeutics
10.1124/mi.5.6.8
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lamour, N. F.
Right arrow Articles by Chalfant, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lamour, N. F.
Right arrow Articles by Chalfant, C. E.
Review

Ceramide-1-phosphate: The "missing" link in eicosanoid biosynthesis and inflammation

Nadia F. Lamour1 and Charles E. Chalfant1,2

1 Department of Biochemistry, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA 23298;
2 Research and Development, Hunter Holmes McGuire Veterans Administration Medical Center, Richmond, VA 23249


{TITLEART_CHALFANT}

It has been over a decade since ceramide kinase (CERK) and its product, ceramide-1-phosphate (C1P), were first reported. Since itscloning, in 2002, CERK has been the subject of an explosion of publications concerning various signal transduction pathways. The roles of this previously overlooked enzyme, as well as those of its product C1P, continue to expand, and their regulatory functions in the production of eicosanoid inflammatory mediators are proving essential to fundamental signal transduction pathways. In particular, C1P is required for the activation and translocation of cPLA2{alpha}, the initial rate-limiting step of eicosanoid synthesis. The potential for inhibitors of CERK to offer a new generation of anti-inflammatory and anti-cancer therapeutics is especially deserving of further study.




This article has been cited by other articles:


Home page
 J. Lipid Res.Home page
W. Hu, J. Bielawski, F. Samad, A. H. Merrill Jr., and L. A. Cowart
Palmitate increases sphingosine-1-phosphate in C2C12 myotubes via upregulation of sphingosine kinase message and activity
J. Lipid Res., September 1, 2009; 50(9): 1852 - 1862.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
W. L. Holland and S. A. Summers
Sphingolipids, Insulin Resistance, and Metabolic Disease: New Insights from in Vivo Manipulation of Sphingolipid Metabolism
Endocr. Rev., June 1, 2008; 29(4): 381 - 402.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Graf, B. Zemann, P. Rovina, N. Urtz, A. Schanzer, R. Reuschel, D. Mechtcheriakova, M. Muller, E. Fischer, C. Reichel, et al.
Neutropenia with Impaired Immune Response to Streptococcus pneumoniae in Ceramide Kinase-Deficient Mice
J. Immunol., March 1, 2008; 180(5): 3457 - 3466.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
D. Leiber, Y. Banno, and Z. Tanfin
Exogenous sphingosine 1-phosphate and sphingosine kinase activated by endothelin-1 induced myometrial contraction through differential mechanisms
Am J Physiol Cell Physiol, January 1, 2007; 292(1): C240 - C250.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
Y. H. Zhang, M. R. Vasko, and G. D. Nicol
Intracellular sphingosine 1-phosphate mediates the increased excitability produced by nerve growth factor in rat sensory neurons
J. Physiol., August 15, 2006; 575(1): 101 - 113.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.